Prolaio

Company profile

About Prolaio

Prolaio is a cardiovascular health technology company that has developed a clinical intelligence platform designed to transform heart care through continuous, high-density data collection and analysis. The company's platform integrates medical insights and data analytics to improve the efficiency, quality, and success probability of cardiovascular clinical development. Using clinical-grade wearable sensors, Prolaio captures physiologic data including pulse, respiration, activity, and electrocardiogram continuously during patients' daily lives, rather than relying on episodic clinic-based assessments. Data collected by mobile relay devices are securely streamed to Prolaio's cloud environment where proprietary AI-based algorithms analyze the information to generate measures of cardiovascular function and capacity. The company serves patients, healthcare providers, and clinical researchers across 22+ countries, with a particular focus on accelerating drug development and enabling precision cardiology. Prolaio has developed FDA-cleared algorithms including eVO2peak, which provides CPET-level cardiopulmonary insights remotely without requiring patients to complete strenuous exercise tests. The company was co-founded by Tassos Gianakakos and operates in partnership with Kardigan, a cardiovascular therapeutics company, to create an integrated approach combining real-world data with drug development. Prolaio's mission is to transform real-world heart data into faster discovery and precision care for functional cures, with the ultimate goal of eradicating avoidable heart conditions.

Company description · Prolaio official website